<DOC>
	<DOCNO>NCT01659099</DOCNO>
	<brief_summary>This study design investigate : - interest new monoclonal antibody ( GA101 ) versus rituximab - interest PET identify early responder Patients receive either rituximab ( standard treatment ) , either GA101 ( study treatment ) , accord randomization arm . The monoclonal antibody associate chemotherapy : CHOP ACVBP accord site 's choice.A PET scan do inclusion , 2 chemotherapy cycle , 4 chemotherapy cycle , identify early patient responder , consolidation ASCT require .</brief_summary>
	<brief_title>GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically proven CD20+ diffuse large B cell lymphoma ( WHO Classification ) Baseline PET scan available least one hypermetabolic lesion Aged ≥ 18 year ≤ 60 year Eligible autologous stem cell transplant Patient previously treat Age adjust International Prognostic Index ( aaIPI ) equal 1 , 2 3 Life expectancy ≥ 3 month Negative HIV , HBV ( antiHBc negativity ) HCV serologies inclusion Having sign write inform consent Having ability willingness comply study protocol procedure Men must agree use barrier method contraception treatment period 3 month last dose GA101 rituximab , ACVBP14 CHOP14 chemotherapy , whichever long Women childbearing potential must agree use adequate method contraception , oral contraceptive , intrauterine device , barrier method contraception treatment period 12 month last dose GA101 , Rituximab , ACVBP14 , CHOP14 chemotherapy , whichever longer Any histological type lymphoma Any history treat nontreated indolent lymphoma . However , patient previously diagnose diffuse large Bcell lymphoma small cell infiltration bone marrow lymph node may include Central nervous system meningeal involvement lymphoma Contraindication drug contain chemotherapy regimen Poor cardiac function ( LVEF &lt; 50 % ) echocardiogram MUGA scan Poor renal function ( creatinine level &gt; 150*mol/l clearance &lt; 30ml/min ) , poor hepatic function ( total bilirubin level &gt; 30µmol/l , transaminase &gt; 2.5 X maximum normal level ) unless abnormality relate lymphoma Poor bone marrow reserve define neutrophil &lt; 1.5 G/L platelet &lt; 100 G/L , unless relate bone marrow infiltration Any history cancer last 5 year , exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma Any serious active disease ( accord investigator 's decision ) Treatment investigational drug within 30 day plan first cycle chemotherapy Pregnant lactate woman Adult patient tutelage Prior history Progressive Multifocal Leukoencephalopathy ( PML )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>aa-IPI &gt; equal 1</keyword>
	<keyword>Diagnosis</keyword>
	<keyword>18 60 year</keyword>
	<keyword>Lymphoma</keyword>
</DOC>